Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav
| dc.contributor.author | Couñago Lorenzo, Felipe | |
| dc.contributor.author | Rodríguez de Dios, Nuria | |
| dc.contributor.author | Montemuiño, Sara | |
| dc.contributor.author | Jové Teixidó, Josep | |
| dc.contributor.author | Martín, Margarita | |
| dc.contributor.author | Calvo Crespo, Patricia | |
| dc.contributor.author | López Mata, Miriam | |
| dc.contributor.author | Thuissard Vasallo, Israel John | |
| dc.contributor.author | Sanz Rosa, David | |
| dc.contributor.author | Taboada, Begoña | |
| dc.contributor.author | Et al. | spa |
| dc.date.accessioned | 2018-12-13T13:32:04Z | |
| dc.date.available | 2018-12-13T13:32:04Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | We wish to thank Jeremic and colleagues for commenting on our recent article [1]. As those authors observed in their comment, our study has several limitations (all of which were described in the article) related to the retrospective design. While we appreciate the feedback provided by those authors, we would like to clarify several points raised in their letter... | spa |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 4.599 JCR (2018) Q1, 12/63 Respiratory System; Q2, 64/230 Oncology | spa |
| dc.description.impact | 1.905 SJR (2018) Q1, 44/226 Cancer Research, 58/381 Oncology, 9/152 Pulmonary and Respiratory Medicine | spa |
| dc.description.impact | No data IDR 2018 | spa |
| dc.description.sponsorship | Sin financiación | spa |
| dc.identifier.citation | Couñago, F., de Dios, N. R., Montemuiño, S., Jové-Teixidó, J., Martin, M., Calvo-Crespo, P., ... & Díaz-Díaz, V. (2018). Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC-ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav. Lung Cancer (Amsterdam, Netherlands), 123, 174. https://doi.org/10.1016/j.lungcan.2018.06.031 | spa |
| dc.identifier.doi | 0.1016/j.lungcan.2018.06.031 | |
| dc.identifier.issn | 0169-5002 | |
| dc.identifier.uri | http://hdl.handle.net/11268/7690 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights.accessRights | restricted access | spa |
| dc.subject.uem | Cáncer | spa |
| dc.subject.unesco | Cáncer | spa |
| dc.title | Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav | spa |
| dc.type | journal article | spa |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 2e374c15-a9f7-4137-99a8-6be419e2c462 | |
| relation.isAuthorOfPublication | 6ec266f2-8e29-4c5c-be70-5f0a58f67db8 | |
| relation.isAuthorOfPublication | 9d1f9950-077f-4566-9a9d-b15d6c626060 | |
| relation.isAuthorOfPublication.latestForDiscovery | 2e374c15-a9f7-4137-99a8-6be419e2c462 |